WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:10000; IF 1:50-200
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Specificity
Phospho-ARK-2 (Y12) Polyclonal Antibody detects endogenous levels of ARK-2 protein only when phosphorylated at Y12.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):WPyGR
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Storage
-15°C to -25°C/1 year(Do not lower than -25°C)
Concentration
1 mg/ml
MW(Observed)
39kD
Modification
Phospho
Clonality
Polyclonal
Isotype
IgG
Related Products
Secondary Antibodies
Goat Anti Mouse IgG(H+L) (HRP)
RS0001
More→
Secondary Antibodies
Goat Anti Rabbit IgG(H+L) (HRP)
RS0002
More→
Primary Antibodies
β-actin (PTR2364) Mouse mAb
YM3028
More→
Primary Antibodies
GAPDH (PTR2304) Mouse mAb
YM3029
More→
Antigen&Target Information
Immunogen:
The antiserum was produced against synthesized peptide derived from human AurB around the phosphorylation site of Tyr12. AA range:1-50
show all
Specificity:
Phospho-ARK-2 (Y12) Polyclonal Antibody detects endogenous levels of ARK-2 protein only when phosphorylated at Y12.The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):WPyGR
This gene encodes a member of the aurora kinase subfamily of serine/threonine kinases. The genes encoding the other two members of this subfamily are located on chromosomes 19 and 20. These kinases participate in the regulation of alignment and segregation of chromosomes during mitosis and meiosis through association with microtubules. A pseudogene of this gene is located on chromosome 8. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Sep 2015],
show all
Function:
Catalytic activity:ATP + a protein = ADP + a phosphoprotein.,cofactor:Magnesium.,Disease:Disruptive regulation of expression is a possibile mechanism of the perturbation of chromosomal integrity in cancer cells through its dominant-negative effect on cytokinesis.,Function:May be directly involved in regulating the cleavage of polar spindle microtubules and is a key regulator for the onset of cytokinesis during mitosis. Component of the chromosomal passenger complex (CPC), a complex that acts as a key regulator of mitosis. The CPC complex has essential functions at the centromere in ensuring correct chromosome alignment and segregation and is required for chromatin-induced microtubule stabilization and spindle assembly. Phosphorylates 'Ser-10' and 'Ser-28' of histone H3 during mitosis.,similarity:Belongs to the protein kinase superfamily. Ser/Thr protein kinase family. Aurora subfamily.,similarity:Contains 1 protein kinase domain.,subcellular location:Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis. Colocalized with gamma tubulin in the mid-body.,subunit:Interacts with TACC1. Associates with RACGAP1 during M phase. Component of the CPC at least composed of BIRC5/survivin CDCA8/borealin, INCENP and AURKB/Aurora-B. Interacts with CDCA1 and NDC80. Interacts with EVI5.,tissue specificity:High level expression seen in the thymus. It is also expressed in the spleen, lung, testis, colon, placenta and fetal liver. Expressed during S and G2/M phase and expression is up-regulated in cancer cells during M phase.,
show all
Cellular Localization:
Nucleus . Chromosome . Chromosome, centromere . Chromosome, centromere, kinetochore . Cytoplasm, cytoskeleton, spindle . Midbody . Localizes on chromosome arms and inner centromeres from prophase through metaphase and then transferring to the spindle midzone and midbody from anaphase through cytokinesis (PubMed:20929775). Colocalized with gamma tubulin in the midbody (PubMed:17726514). Proper localization of the active, Thr-232-phosphorylated form during metaphase may be dependent upon interaction with SPDYC (PubMed:20605920). Colocalized with SIRT2 during cytokinesis with the midbody (PubMed:17726514). Localization (and probably targeting of the CPC) to the inner centromere occurs predominantly in regions with overlapping mitosis-specific histone phosphorylations H3pT3 and H2ApT12 (PubMed:20929775). .
show all
Tissue Expression:
High level expression seen in the thymus. It is also expressed in the spleen, lung, testis, colon, placenta and fetal liver. Expressed during S and G2/M phase and expression is up-regulated in cancer cells during M phase. ; [Isoform 3]: Not expressed in normal liver, high expression in metastatic liver.